Hereditary hemorrhagic telangiectasia
MONDO:0019180A disorder of angiogenesis leading to arteriovenous dilatations: cutaneo-mucosal hemorrhagic telangiectasias and visceral shunting.
Also known as: HHT, Osler-Weber-Rendu disease, Rendu-Osler disease, Rendu-Osler-Weber disease, hereditary hemorrhagic telangiectasia, telangiectasia, hereditary Hemorrahagic, of Rendu, Osler, telangiectasia, hereditary hemorrhagic
39 clinical trials for this condition and its sub-types, 34 tagged with Hereditary hemorrhagic telangiectasia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Hereditary hemorrhagic telangiectasia
-
New drug aims to tame rare bleeding disorder
Disease control OngoingThis study tests a new medicine called ALN-6400 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. First, healthy volunteers will receive a single dose to check safety. Then, HHT patients will recei…
Phase 1/2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Cancer drug shows promise for rare bleeding disorder
Disease control OngoingThis phase 2 trial tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce chronic bleeding and iron-deficiency anemia in people with hereditary hemorrhagic telangiectasia (HHT). HHT causes abnormal blood vessels that bleed easily. The study involves 33 adul…
Phase 2 • Sponsor: Hanny Al-Samkari, MD • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
HHT drug trial pulled before it even started
Disease control CancelledThis was a planned early-stage study of a new drug called TER-1754 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and abnormal blood vessels. The trial aimed to test safety and find the right dose, but it was withdrawn bef…
Phase 1 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a cancer pill stop debilitating nosebleeds? new trial hopes so.
Disease control OngoingThis study tests whether a low dose of pazopanib, a drug currently used for cancer, can reduce severe nosebleeds and improve anemia in people with hereditary hemorrhagic telangiectasia (HHT). About 70 participants will take either the drug or a placebo daily for 24 weeks. Researc…
Phase 2/3 • Sponsor: Cure HHT • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug aims to stop nosebleeds in rare genetic disorder
Disease control OngoingThis study tests a new drug called VAD044 in 75 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and anemia. The first part compares two doses of VAD044 against a placebo to see if it safely reduces the number, length, and sever…
Phase 1/2 • Sponsor: Vaderis Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can a cancer drug tame rare bleeding Disorder's heart complications?
Disease control By invitation onlyThis study looks at whether the drug bevacizumab can help people with a rare condition called hereditary hemorrhagic telangiectasia (HHT) who have severe liver problems leading to high heart output and possible heart failure. Researchers will check heart function before and after…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New registry aims to unlock secrets of rare bleeding disorder
Knowledge-focused OngoingThis study is creating a registry of people with Hereditary Hemorrhagic Telangiectasia (HHT), a rare condition that causes abnormal blood vessels and frequent nosebleeds. Researchers will collect health information from about 1,000 adults over many years to see how the disease ch…
Sponsor: Unity Health Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New registry monitors VBX stent graft in Real-World use
Knowledge-focused OngoingThis study is a registry that collects safety and performance data on the GORE® VIABAHN® VBX Stent Graft when used in peripheral vessels. It involves 280 adults who need this device to treat peripheral vascular disease. The goal is to see how well the stent graft works and if the…
Sponsor: W.L.Gore & Associates • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC